10-Q: AngioDynamics Reports Q3 2025 Results: Med Tech Growth Offsets Divestiture Impact

AngioDynamics' Q3 2025 results show a decrease in overall revenue due to divestitures, but growth in the Med Tech segment partially offset the decline.

Summary

• AngioDynamics reported a net loss of $4.4 million, or $0.11 per share, on net sales of $72.0 million for the third quarter of fiscal year 2025.
• This compares to a net loss of $187.7 million, or $4.67 per share, on net sales of $75.2 million for the same period last year.
• For the nine months ended February 28, 2025, the company reported a net loss of $27.9 million, or $0.68 per share, on net sales of $212.3 million.
• This is compared to a net loss of $170.9 million, or $4.26 per share, on net sales of $232.9 million for the same period in the prior year.
• The decrease in revenue is attributed to the divestiture of the PICCs, Midline, dialysis, and BioSentry businesses, as well as the discontinuation of the RadioFrequency Ablation and Syntrax product lines, impacting sales by $9.2 million and $33.5 million for the three and nine months ended February 28, 2025, respectively.
• Med Tech revenue grew by 21.3% in the third quarter of fiscal year 2025, while Med Device revenue declined by 17.6%.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reports a net loss, there are positive aspects such as growth in the Med Tech segment and improved gross profit margins. The company is also executing on a restructuring plan expected to generate cost savings.

Positives

• Med Tech segment experienced significant growth, with net sales increasing by 21.3% in Q3 2025.
• Gross profit margin improved to 54.0% in Q3 2025.
• Net loss decreased significantly compared to the same period in the prior year, from $187.7 million to $4.4 million.
• The company achieved a sales milestone related to divested products, resulting in a $5.5 million receivable.
• Cash used in operations decreased by $4.2 million to $28.9 million.

Negatives

• Overall net sales decreased by 4.2% in Q3 2025 due to divestitures and product line discontinuations.
• Med Device segment experienced a decline in net sales, decreasing by 17.6% in Q3 2025.
• The company reported a net loss of $4.4 million for the quarter.
• Cash and cash equivalents decreased from $76.1 million as of May 31, 2024, to $44.8 million as of February 28, 2025.

Risks

• The current macroeconomic environment continues to impact the business, including the ability to manufacture products, supply chain reliability, labor shortages, and inflation.
• The company is involved in various legal proceedings, including product liability claims related to port products.
• The company's future performance depends on the introduction of new and innovative products, which requires ongoing investments in research and development.
• Foreign currency exchange rate fluctuations could negatively impact sales and gross profit.

Future Outlook

The company expects its businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products, and increasing its presence internationally. The restructuring activities associated with the modified Plan are still expected to be completed in the third quarter of fiscal year 2026. The modified Plan is still expected to generate $15.0 million in annual cost savings starting in fiscal year 2027.

Management Comments

• Management continues to evaluate the company's liquidity position, communicate with and monitor the actions of customers and suppliers, and review near-term financial performance.
• Management focuses on company-wide and segment revenue and gross margin and company-wide operating income, earnings per share and cash flow from operations.

Industry Context

The company's financial performance is impacted by changing market dynamics, including value-based purchasing, healthcare provider consolidation, the increased role of the consumer in healthcare decision-making, and an aging population. The company's growth is also impacted by changes within the sector, such as competitor mergers, changes in the regulatory environment, and fluctuations in the global economy.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• A more detailed analysis would require a comparison of AngioDynamics' financial metrics (e.g., revenue growth, gross margin, operating expenses) to those of its direct competitors, such as Boston Scientific, Medtronic, and Cook Medical.
• Additionally, benchmarking against industry averages for medical device companies would provide further context.

Legal Proceedings

• The company is defending approximately 120 product liability claims involving the company's port products.
• The company made a one-time lump sum payment to BD in the amount of $7.0 million, $3.0 million which was paid within 5 business days of execution of the Settlement Agreement, and the remainder is payable in installments during 12 month period ending March 31, 2025.
• The Company will also make six minimum annual payments to BD of $2.5 million starting in fiscal year 2025, and potential additional payments if six percent (6%) of annual net sales of the Company's port products exceed the minimum payment.
• A contingent payment of $3.0 million will be due from the Company to BD if the Federal Circuit reverses or vacates the District Courts findings of invalidity with respect to the patent claims at issue in the case.

Stakeholder Impact

• Shareholders: The share repurchase program may positively impact shareholder value.
• Employees: The restructuring plan may result in job losses, but also aims to improve the company's overall operations.
• Customers: The company's focus on new and innovative products aims to improve the quality of life for patients.
• Suppliers: The company is monitoring the actions of its suppliers in light of the current macroeconomic environment.

Next Steps

• Complete the restructuring activities associated with the modified Plan, expected in the third quarter of fiscal year 2026.
• Continue to execute the share repurchase program, with $13.3 million remaining available as of February 28, 2025.
• Receive the $5.5 million payment related to the sales milestone achieved in the third quarter of fiscal year 2025, expected in the fourth quarter of fiscal year 2025.

Key Dates

Keywords

AngioDynamics, financial results, Q3 2025, Med Tech, Med Device, net sales, gross profit, net loss, divestiture, restructuring, share repurchase, medical devices